Korro Bio, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
KRRO$15.73+5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(amounts in thousands, except share amounts)
| Common Stock · Treasury Stock · AdditionalPaid- · AccumulatedOtherComprehensive · Accumulated · TotalStockholders' | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | In Capital | Income (Loss) | Deficit | Equity | |
| Balance at December 31, 2025 | 9,417,295 | $9 | — | $— | $435,064 | $212 | $(383,846) | $51,439 |
| Exercises of stock options | 1,487 | — | — | — | 17 | — | — | 17 |
| Stock-based compensation expense | — | — | — | — | 2,731 | — | — | 2,731 |
| Issuance of common stock in connection with the at-the-market program, net of offering costs | 501,861 | — | — | — | 5,020 | — | — | 5,020 |
| Issuance of common stock and pre-funded warrants in connection with the private placement, net of offering costs | 4,501,928 | 5 | — | — | 80,253 | — | — | 80,258 |
| Other comprehensive loss | — | — | — | — | — | (207) | — | (207) |
| Net loss | — | — | — | — | — | — | (19,625) | (19,625) |
| Balance at March 31, 2026 | 14,422,571 | $14 | — | $— | $523,085 | $5 | $(403,471) | $119,633 |
| Stock-based compensation expense | — | — | — | — | 2,703 | — | — | 2,703 |
| Vesting of restricted stock units | 233,075 | — | — | — | — | — | — | — |
| Vesting of performance stock units | 50,000 | — | — | — | — | — | — | — |
| Other comprehensive loss | — | — | — | — | — | (194) | — | (194) |
| Net loss | — | — | — | — | — | — | (18,916) | (18,916) |
| Balance at June 30, 2026 | 14,705,646 | $14 | — | $— | $525,788 | $(189) | $(422,387) | $103,226 |
| Stock-based compensation expense | — | — | — | — | 2,812 | — | — | 2,812 |
| Vesting of restricted stock units | 20,000 | — | — | — | — | — | — | — |
| Issuance of pre-funded warrants in exchange for common stock | — | — | (1,000,000) | (12,120) | 12,120 | — | — | — |
| Other comprehensive loss | — | — | — | — | — | (116) | — | (116) |
| Net loss | — | — | — | — | — | — | (17,548) | (17,548) |
| Balance at September 30, 2026 | 14,725,646 | $14 | (1,000,000) | $(12,120) | $540,720 | $(305) | $(439,935) | $88,374 |
| Balance at December 31, 2024 | 9,377,259 | $9 | — | $— | $426,724 | $268 | $(266,586) | $160,415 |
| Exercises of stock options | 11,643 | — | — | — | 172 | — | — | 172 |
| Stock-based compensation expense | — | — | — | — | 1,761 | — | — | 1,761 |
| Other comprehensive loss | — | — | — | — | — | (4) | — | (4) |
| Net loss | — | — | — | — | — | — | (23,387) | (23,387) |
| Balance at March 31, 2025 | 9,388,902 | $9 | — | $— | $428,657 | $264 | $(289,973) | $138,957 |
| Exercises of stock options | 1,940 | — | — | — | 5 | — | — | 5 |
| Stock-based compensation expense | — | — | — | — | 1,998 | — | — | 1,998 |
| Other comprehensive loss | — | — | — | — | — | (87) | — | (87) |
| Net loss | — | — | — | — | — | — | (25,770) | (25,770) |
| Balance at June 30, 2025 | 9,390,842 | $9 | — | $— | $430,660 | $177 | $(315,743) | $115,103 |
| Exercises of stock options | 7,142 | — | — | — | 128 | — | — | 128 |
| Stock-based compensation expense | — | — | — | — | 1,825 | — | — | 1,825 |
| Other comprehensive income | — | — | — | — | — | 37 | — | 37 |
| Net loss | — | — | — | — | — | — | (18,061) | (18,061) |
| Balance at September 30, 2025 | 9,397,984 | $9 | — | $— | $432,613 | $214 | $(333,804) | $99,032 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.